Despite Teva’s English court of appeal defeat, Arrow declarations remain a valuable weapon for generics
The judgment is one of only a few decisions addressing the pre-emptive litigation defence
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.